5-Amino-1MQ
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
5-Amino-1MQ is listed as metabolic / nnmt inhibitor.
- •Fat loss
- •Muscle preservation (research)
Regulatory status: Research chemical — not approved for human use.
Structure & Properties
Compound: 5-Amino-1MQ; also known as 5A1MQ, NNMT inhibitor.
Pharmacologic class: Metabolic / NNMT Inhibitor.
Known delivery routes: Oral.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — restores cellular NAD+/SAM balance, enhances adipocyte lipolysis and myocyte regeneration.
- •Reduces adiposity in rodents
- •Improves muscle stem-cell function
- •May support metabolic flexibility
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Pre-clinical (rodent models of obesity & sarcopenia)
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once daily oral, typically morning with or without food.
Potential interactions and combinations to avoid
- •No well-characterized interactions; avoid stacking multiple experimental metabolic agents
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Unknown human safety
- •Potential off-target methylation effects
- •No long-term data
Contraindications
- •Pregnancy / lactation
- •Hepatic impairment (caution)
- •Concurrent NAD-precursor or methyl-donor protocols without methylation monitoring
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 50–150 mg/day (anecdotal human use)
Frequency: Daily
Cycling: Reported 8–12 week cycles in user protocols; not validated.
Oral
Once daily AM.
Capsule (50–150 mg). With or without food.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •GLP-1 therapy or caloric restriction for adjunctive lean-mass support
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Research-grade; human data limited.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning, with or without food — pairs with daytime activity.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
5-Amino-1MQ has no injection site — see the routes below.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Reported 8–12 week cycles in user protocols; not validated.
Timing & Interactions
- ·No well-characterized interactions; avoid stacking multiple experimental metabolic agents
- ·GLP-1 therapy or caloric restriction for adjunctive lean-mass support
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on 5-Amino-1MQ and sync them to Vial Lab.
Benefits
- ·Reduces adiposity in rodents
- ·Improves muscle stem-cell function
- ·May support metabolic flexibility
Risks
- ·Unknown human safety
- ·Potential off-target methylation effects
- ·No long-term data
Contraindications
- ·Pregnancy / lactation
- ·Hepatic impairment (caution)
- ·Concurrent NAD-precursor or methyl-donor protocols without methylation monitoring
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research chemical — not approved for human use
Veterinary Use (Pets)
No established veterinary protocol for 5-Amino-1MQ. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.